arrow
S

Scott L. Friedman

Icahn School of Medicine at Mount Sinai
H指数:144
被引数:9.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PDGFRß targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation

靶向PDGFRß的正电子发射断层扫描作为活化肝星状细胞的非侵入性生物标志物:临床转化前的最后步骤

2025-12-130
OAAI
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis

内皮-间质转化:一种可靶向机制,参与肝硬化门静脉血栓形成

2025-10-010
PRE
ACLY inhibition promotes tumour immunity and suppresses liver cancer

ACLY抑制促进肿瘤免疫和抑制肝癌

Nature
IF48.5
2025-07-300
OA
Real-world Comparison of SAFE and FIB-4 Scores for Assessing MASLD-Related Fibrosis in a highly diverse urban MASLD population

SAFE评分和FIB-4评分在评估高度多样化城市MASLD人群MASLD相关纤维化方面的真实世界比较

2025-07-100
PRE
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

细胞外基质相关诊断和治疗的研究进展

2025-03-100
OAAI
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

解决代谢功能障碍相关的脂肪性肝病 (MASLD) 和代谢功能障碍相关的脂肪性肝炎 (MASH) 的全球高负担和不断上升: 从日益增长的患病率到支付方的角度

2025-02-180
PRE
Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation

CEACAM1在肝星状细胞中的条件缺失导致其活化

2024-10-013
OAAI
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

基于与人类代谢功能障碍相关的脂肪变性肝病 (MASLD) 的接近程度,对小鼠饮食模型进行无偏排名

2024-06-1233
OA